晶泰科技：2025年上半年收入同比增长404%，首次实现半年盈利

Core Insights - In the first half of 2025, XtalPi reported a revenue increase of 404% year-on-year, reaching 517 million RMB, and achieved a net profit of 141 million RMB, marking its first half-year profitability [1] - XtalPi is an innovative R&D platform leveraging quantum physics, AI, and robotics, providing drug and materials science development solutions [1] - The company is the first specialized technology firm to be listed on the Hong Kong Stock Exchange under Chapter 18C of the listing rules [1] - Among the top 20 global pharmaceutical companies, 16 are clients of XtalPi [1] Revenue Breakdown - The revenue from drug discovery solutions grew significantly, increasing from 60.85 million RMB in the first half of 2024 to 435.2 million RMB, a growth of 615.2% [2] - This growth in drug discovery solutions was driven by substantial upfront payments from major collaborations and the successful achievement of multiple pipeline milestones [2] - Revenue from intelligent robotics solutions also saw rapid growth, rising from 41.78 million RMB in the first half of 2024 to 81.86 million RMB, an increase of 95.9% [2] - The growth in intelligent robotics solutions was primarily fueled by the rapid expansion of automated chemical synthesis services and XtalPi's R&D solutions [2]